menu
    • menu
    [{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"MEI Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyowa Kirin \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ MEI Pharma"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Zandelisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"MEI Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kyowa Kirin \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ MEI Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Zandelisib

    Menu

    Zandelisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology As...

                            Details : Clinical and preclinical data suggest that ME-401 (zandelisib) distinct characteristics include prolonged target binding, preferential cellular accumulation, high volume of distribution throughout body tissues, and an approx, 28-hour half-life suitable f...

                            Product Name : ME-401

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 05, 2022

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kyowa Kirin

                            Japan arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Kyowa Kirin

                            Japan arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zandelisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : MEI Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patien...

                            Details : ME-401 (zandelisib), a selective PI3Kδ inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, treatment for patients with B-cell malignancies.

                            Product Name : ME-401

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 18, 2022

                            Lead Product(s) : Zandelisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : MEI Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid C...

                            Details : ME-401 (zandelisib), an orally administered investigational phosphatidylinositol 3- kinase delta ("PI3Kδ") inhibitor in clinical development for the treatment of B-cell malignancies

                            Product Name : ME-401

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 06, 2022

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zandelisib,Ibrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022

                            Details : Data from preclinical studies with ME-401 (zandelisib), a selective PI3Kδ inhibitor, ex vivo in normal human T cells and in vivo in a murine CLL model suggest that zandelisib has immunomodulatory properties on human T cells.

                            Product Name : ME-401

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 04, 2022

                            Lead Product(s) : Zandelisib,Ibrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Resea...

                            Details : ME-401 (zandelisib), an oral and selective inhibitor of PI3K delta, is being evaluated in multiple clinical studies, including COASTAL and TIDAL study, in patients with follicular and marginal zone lymphomas and other B-cell malignancies.

                            Product Name : ME-401

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 03, 2022

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of...

                            Details : ME-401 (zandelisib), a selective PI3Kδ inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, potential therapeutic option for patients with B-cell malignancies.

                            Product Name : ME-401

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 18, 2022

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zandelisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinica...

                            Details : ME-401 (Zandelisib), an oral and selective inhibitor of PI3Kδ, is being evaluated in multiple clinical studies, including COASTAL, a Phase 3 study, and TIDAL, a Phase 2 study, in patients with relapsed and refractory follicular and marginal zone lymphom...

                            Product Name : ME-401

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 26, 2022

                            Lead Product(s) : Zandelisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zandelisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recen...

                            Details : ME-401 (zandelisib), a selective PI3Kδ inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, treatment for patients with B-cell malignancies.

                            Product Name : ME-401

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 12, 2022

                            Lead Product(s) : Zandelisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Ann...

                            Details : Clinical trials are investigating the efficacy and safety of ME-401 (zandelisib) as a single agent and in combination with other modalities while administered on an Intermittent Dosing Regimen (ID) and in a time-limited manner when dosed in combination.

                            Product Name : ME-401

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 06, 2022

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MEI Pharma

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA

                            Details : ME-401 (zandelisib), a selective phosphatidylinositol-3-kinase inhibitor, an investigational cancer treatment for patients with B-cell malignancies, demonstrated a 70.3% objective response rate in Phase 2 TIDAL study.

                            Product Name : ME-401

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 24, 2022

                            Lead Product(s) : Zandelisib,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Kyowa Kirin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth